Compare AbbVie Inc (ABBV) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? AbbVie Inc trades at $253.24 (market cap $449.91B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $252.16 (market cap $47.86B). The key difference: AbbVie Inc is far larger — about 9.4× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and AbbVie Inc pays a 2.72% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| ABBV | TTWO | |
|---|---|---|
Market Cap | $449.91B | $47.86B |
Sector | Health | Media |
52-Week High | $261.07 | $262.29 |
52-Week Low | $184.85 | $189.69 |
Enterprise Value | $513.38B | $48.83B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Take-Two Interactive (TTWO) trades at $257.79, up 1.12% with strong bullish momentum driven by Grand Theft Auto VI pre-orders and recent earnings beats. The stock shows technical strength with bullish moving averages, though RSI indicates overbought conditions. Despite negative net income margins, revenue growth to $5.63B in 2025 and analyst consensus of $302.50 price target reflect optimism around the GTA VI launch in November 2026.
Outlook remains positive with GTA VI as a major catalyst, but risks include high debt levels and profitability challenges. Institutional sentiment is strongly bullish with 79% buy ratings, yet investors should monitor execution risks and competitive pressures in the gaming sector. The stock's valuation metrics like P/S of 7.14 suggest growth expectations are priced in.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
